Insmed Incorporated (INSM) |
|
17.4 -0.02 (-0.11%)
|
03-20 09:45 |
|
Open: |
17.27 |
Pre. Close: |
17.42 |
|
High:
|
17.54 |
Low:
|
17.29 |
|
Volume:
|
13,948 |
Market Cap:
|
2,373(M) |
|
|
|
Technical analysis |
as of: 2023-03-20 9:17:13 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 22.76  One year: 24.71 |
| Support: |
Support1: 16.79 Support2: 13.97 |
| Resistance: |
Resistance1: 19.49 Resistance2: 21.15 |
| Pivot: |
19.17 |
| Moving Average: |
MA(5): 17.87 MA(20): 19.49
MA(100): 19.35 MA(250): 21.17 |
| MACD: |
MACD(12,26): -0.7 Signal(9): -0.5 |
| Stochastic oscillator: |
%K(14,3): 9.3 %D(3): 11.7 |
| RSI: |
RSI(14): 30.5 |
| 52-week: |
High: 28.94 Low: 16.4 |
| Average Vol(K): |
3-Month: 1,305 (K) 10-Days: 1,316 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ INSM ] has closed above bottom band by 11.3%. Bollinger Bands are 42.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
17.54 - 17.66 |
17.66 - 17.75 |
|
Low:
|
16.48 - 16.65 |
16.65 - 16.77 |
|
Close:
|
17.19 - 17.42 |
17.42 - 17.59 |
|
Company Description |
|
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey. |
Headline News |
Sun, 19 Mar 2023
Peregrine Capital Management LLC Trims Holdings in Insmed ... - MarketBeat
Sat, 11 Mar 2023
Moore Capital Management LP purchases new Insmed Incorporated ... - Best Stocks
Fri, 10 Mar 2023
Insmed Incorporated (NASDAQ:INSM) Position Raised by Castleark ... - MarketBeat
Fri, 03 Mar 2023
Insmed Reports Inducement Grants Under NASDAQ Listing Rule ... - Galveston County Daily News
Mon, 27 Feb 2023
Insmed Incorporated (NASDAQ:INSM) to Report Earnings of ($1.03 ... - Best Stocks
Thu, 23 Feb 2023
Insmed Reports Fourth Quarter and Full Year 2022 Financial ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
136 (M) |
| Shares Float |
135 (M) |
|
% Held by Insiders
|
1.4 (%) |
|
% Held by Institutions
|
107.6 (%) |
|
Shares Short
|
10,420 (K) |
|
Shares Short P.Month
|
11,420 (K) |
Stock Financials |
|
EPS
|
-3.73 |
|
EPS Est Next Qtl
|
-0.67 |
|
EPS Est This Year
|
-2.71 |
|
EPS Est Next Year
|
-2.28 |
|
Book Value (p.s.)
|
0.64 |
|
Profit Margin (%)
|
-196.3 |
|
Operating Margin (%)
|
-194.9 |
|
Return on Assets (ttm)
|
-20.7 |
|
Return on Equity (ttm)
|
-193.3 |
|
Qtrly Rev. Growth
|
5.6 |
|
Gross Profit (p.s.)
|
1.39 |
|
Sales Per Share
|
1.79 |
|
EBITDA (p.s.)
|
-3.46 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-400 (M) |
|
Levered Free Cash Flow
|
-198 (M) |
Stock Valuations |
|
PE Ratio
|
-4.69 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
26.8 |
|
Price to Sales
|
9.68 |
|
Price to Cash Flow
|
-5.94 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
